Bio‑Rad Laboratories and Myriad RBM, a wholly owned subsidiary of Myriad Genetics, have partnered to develop and distribute high-quality immunoassay kits. Myriad RBM has granted Bio-Rad exclusive distribution rights, for research purposes, to its catalog of quantitative multiplexed immunoassays currently available to run on Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MAGPIX instruments.
 
Myriad RBM’s assays address needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, and cardiovascular and other diseases. The new assays expand Bio-Rad’s current suite of assays.
 
“Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu,” said Brad Crutchfield, Bio-Rad vice president and group manager, Life Science Group. “Moving forward, Myriad RBM and Bio‑Rad will collaborate to design new products to meet the evolving requirements of our customers.”
 
“This agreement combines Myriad RBM’s industry-leading menu of multiplexed immunoassays with Bio‑Rad’s unrivaled global commercial distribution capabilities,” said Craig Benson, president of Myriad RBM. “Our partnership with Bio‑Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care.”